Prakt. lékáren. 2008; 4(5): 230-234

Spolehlivá ochrana po očkování proti papillomavirovým nákazám

RNDr. Marek Petráš
Specialista v oboru vakcinologie, Praha

Již v roce 2006 byla u nás k tomuto očkování používaná čtyřvalentní vakcína Silgard (v některých zemích s názvem Gardasil). O rok později byla na našem trhu nabídnuta i bivalentní vakcína Cervarix. V současnosti máme v České republice k dispozici obě dvě celosvětově dostupné komerční vakcíny určené k prevenci papillomavirových nákaz.Konkurenční prostředí vyvolává mnoho diskutabilních pohledů na obě vakcíny a vyzdvihují se jejich jednotlivé přednosti. Cílem tohoto článku je shrnout poznatky zaměřené na účinnost tohoto očkování a případně vyvrátit či potvrdit některé sporné otázky.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráš M. Spolehlivá ochrana po očkování proti papillomavirovým nákazám. Praktické lékárenství. 2008;4(5):230-234.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177(6): 1710-1714. Go to original source... Go to PubMed...
    2. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135-2145. Go to original source... Go to PubMed...
    3. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh- Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69(6): 3959-3963. Go to original source... Go to PubMed...
    4. Brown D, for the FUTURE Study Group. HPV Type 6/11/16/18 Vaccine: First analysis of crossprotection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. ICAAC Chicago. September 2007.
    5. Dawar M, Dobson S, Deeks S. Literature review on HPV 6, 11, 16 and 18: Disease and Vaccine Characteristics; PHAC, June 2007.
    6. De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, Urbain J, Moser M. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol. 2000 Jun; 12(6): 807-815. Go to original source... Go to PubMed...
    7. Dubin GftHVASI, GlaxoSmithKline Biologicals, Rixensart, Belgium. Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus-like particle vaccine (VLP) with novel AS04 adjuvant in pre-teens/adolescents. Abstract no:4042. ICAAC 2005: GSK; 2005.
    8. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. Jul 29 2004; 22(21-22): 2943-2952. Go to original source... Go to PubMed...
    9. Future II Study Group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19): 1915-1927. Go to original source... Go to PubMed...
    10. Gall S, Teixeira J, Wheeler C, Naud P, Harper D, Franco E, Quint W, Zahaf T, Schuind A, Jenkins D, Dubin G. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. AACR Meeting Abstracts, Apr 2007; 2007: 4900.
    11. Garçon N, Chomez P, Van Mechelen M.GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6(5): 723-739. Go to original source... Go to PubMed...
    12. Gardasil(R) prescribing information. Merck & Co., Inc., June 2006.
    13. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 10 2007; 356(19): 1928-1943. Go to original source... Go to PubMed...
    14. Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 2000; 68(3): 147-151. Go to original source... Go to PubMed...
    15. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 14; 24(33-34): 5937-5949. Go to original source... Go to PubMed...
    16. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19(13-14): 1783-1793. Go to original source... Go to PubMed...
    17. Guidance for the introduction of HPV vaccines in EU countries; Guidance Report | Stockholm, 2008.
    18. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 13-19 2004; 364(9447): 1757-1765. Go to original source... Go to PubMed...
    19. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 15, 2006; 367(9518): 1247-1255. Go to original source... Go to PubMed...
    20. Human papillomavirus vaccine. Drug Facts and Comparisons. Efacts (online). 2006. Available from Wolters Kluwer Health, Inc. (accessed 11/1/06).
    21. Human Papilloomavirus (HPV) Vacines; Quadrivalent HPV Vaccien Cross-Protection; CDC, Advisory Committee on Immunization Practices Atlanta, Georgia, 24-25, 2007; 59-64.
    22. Immunisation Handbook 2006, Chapter 19: New Vaccines.
    23. Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: Commercial Research & Development. Vaccine. 21, 2006; 24 Suppl 3: S99-S105. Go to original source... Go to PubMed...
    24. Jansen KU, Rosolowsky M, Schutz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13: 1509-1514, 1995. Go to original source... Go to PubMed...
    25. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions. Lancet 2007; 369: 1693-1702. Go to original source... Go to PubMed...
    26. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 21, 2002; 347(21): 1645-1651. Go to original source... Go to PubMed...
    27. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176(5): 1141-1145. Go to original source... Go to PubMed...
    28. Ltd. MFC. GardasilTM Product Monograph. Vol 102682; 2006.
    29. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107(1): 18-27. Go to original source... Go to PubMed...
    30. MRL Clinical Study Report MS. Study of pilot manufacturing lot of HPV 16 virus-like particle (VLP) vaccine in the prevention of HPV 16 infection in 16- to 23-year old females. Vol 005; 2005.
    31. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 6, 2003; 95(15):1128-1137. Go to original source... Go to PubMed...
    32. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. for the HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 viruslike-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised control trial. Lancet 2007: 369: 2161-2170. Go to original source... Go to PubMed...
    33. Pagliusi SR, Dillner J, Pawlita M, Quint WG, Wheeler CM, Ferguson M. Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assaysan update. Vaccine. 21, 2006; 24 Suppl 3: S193-S200. Go to original source... Go to PubMed...
    34. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007; 26(3): 201-209. Go to original source... Go to PubMed...
    35. Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997; 65(8): 3239-3247. Go to original source... Go to PubMed...
    36. See http://www.cdc.gov/nip/ACIP/mtg-slides-feb06.htm#hpv.
    37. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacother 2006; 40: 1344-1352. Go to original source... Go to PubMed...
    38. Schwarz TF, Dubin GO. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. HPV vacine for study investigators for adult women, GlaxoSmithKline Biologicals. Paper presented at: 2006 ASCO Annual Meeting Proceedings Part 1, 2006. Go to original source...
    39. Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil(R)). Drugs 2006; 66: 1263-1271. Go to original source... Go to PubMed...
    40. Skjeldestad FEFISC. Prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (GardasilTM) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Paper presented at: Infectious Disease Society of America 43rd Annual Meeting, 2005; San Francisco, California. Go to original source...
    41. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine. 21, 2006; 24 Suppl 3: S106-S113. Go to original source... Go to PubMed...
    42. The Future II Study Group. Effect of prophylactic human papillomavirus L1 viruslike-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868. Go to original source... Go to PubMed...
    43. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927. Go to original source... Go to PubMed...
    44. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-5583. Go to original source... Go to PubMed...
    45. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5): 271-278. Go to original source... Go to PubMed...
    46. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 4, 2006; 95(11): 1459-1466. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.